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Abstract
Background: Although subgroup analyses in clinical trials may provide evidence for individualised medicine, their
conduct and interpretation remain controversial.
Methods: Subgroup effect can be defined as the difference in treatment effect across patient subgroups.
Cumulative subgroup analysis refers to a series of repeated pooling of subgroup effects after adding data from
each of related trials chronologically, to investigate the accumulating evidence for subgroup effects. We illustrated
the clinical relevance of cumulative subgroup analysis in two case studies using data from published individual
patient data (IPD) meta-analyses. Computer simulations were also conducted to examine the statistical properties of
cumulative subgroup analysis.
Results: In case study 1, an IPD meta-analysis of 10 randomised trials (RCTs) on beta blockers for heart failure reported
significant interaction of treatment effects with baseline rhythm. Cumulative subgroup analysis could have detected
the subgroup effect 15 years earlier, with five fewer trials and 71% less patients, than the IPD meta-analysis which first
reported it. Case study 2 involved an IPD meta-analysis of 11 RCTs on treatments for pulmonary arterial hypertension
that reported significant subgroup effect by aetiology. Cumulative subgroup analysis could have detected the
subgroup effect 6 years earlier, with three fewer trials and 40% less patients than the IPD meta-analysis. Computer
simulations have indicated that cumulative subgroup analysis increases the statistical power and is not associated with
inflated false positives.
Conclusions: To reduce waste of research data, subgroup analyses in clinical trials should be more widely conducted
and adequately reported so that cumulative subgroup analyses could be timely performed to inform clinical practice
and further research.
Keywords: Subgroup analysis, Individual patient data, Cumulative meta-analysis, Randomised controlled trials,
Individualised medicine
Background
Randomised controlled trials (RCTs) provide the most
valid evidence on effects of treatments and healthcare
interventions, and results of RCTs are usually reported as
estimated average effects. However, average effects from
RCTs may not be generalisable to individual patients in
clinical practice, because of heterogeneity across individ-
ual patients in terms of demographic characteristics,
genetic features, disease severity, co-morbidities and other
factors [1, 2]. Subgroup analysis is often used in RCTs to
investigate differences in treatment effect between patients
with different characteristics [3]. A study found that
subgroup analyses were reported in 44% of the 469 RCTs
published in core clinical journals in 2007 [4].
There are well known limitations with subgroup
analyses in RCTs, including possible false positive
subgroup effects due to multiple testing, and false nega-
tive subgroup results due to inadequate statistical power
[5]. It has been recommended that only a small number
of pre-specified subgroup analyses in RCTs should be
conducted using appropriate statistical methods [6, 7].
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Methods have been recommended for assessing credibil-
ity of subgroup analyses in RCTs [8, 9]. However, the
conduct, reporting and interpretation of subgroup
analysis in RCTs are still controversial [10, 11].
Although meta-analyses of RCTs are generally accepted
for estimating the overall treatment effects, subgroup ana-
lyses in meta-analysis are hampered because of inadequate
data on subgroups in published trials [12]. Meta-analysis
using individual patient data (IPD) has been increasingly
used to conduct more statistically powerful subgroup
analyses by pooling data from multiple trials [13]. A recent
study found that significant subgroup effects were identi-
fied in 44 IPD meta-analyses and in only three aggregate
data meta-analyses among 204 paired IPD meta-analyses
and aggregate data meta-analyses [14].
Previous studies regarding subgroup analysis method-
ology have focused mainly on the results of individual trials,
and research data may have been wasted for detecting
clinically important differences in treatment effects between
patient subgroups. The objective of the current study is to
illustrate the usefulness and statistical properties of cumula-
tive subgroup analysis by providing empirical evidence from
case studies and computing simulations.
Methods
Patient characteristics at baseline are relevant subgroup
variables in the current study, although subgroup ana-
lyses may also be conducted by other types of variables.
Subgroup effect in a trial is defined as the interaction of
treatment with a subgroup variable, or the difference in
treatment effect across subgroups [5]. In the current
study, subgroup effect is measured by the ratio of rela-
tive treatment effects between subgroups (e.g. ratio of
odds ratios, ratio of hazard ratios) for binary outcomes,
and the difference in absolute mean differences or
standardised mean differences between subgroups for
continuous outcomes.
Cumulative subgroup analysis
For estimating overall treatment effects, cumulative meta-
analysis consists of a series of repeated meta-analyses after
adding data from each new trial chronologically [15]. It
can be used to reveal the contribution of individual trials
to the overall estimate, and to identify the earliest time at
which the pooled effect becomes statistically significant.
We applied the method of cumulative meta-analysis to in-
vestigate changes in estimates of subgroup effects over
time. Statistical methods for cumulative subgroup analysis
are presented in Additional file 1.
Case studies
We searched PubMed to identified recently published
IPD meta-analyses with sufficient data to perform cumu-
lative subgroup analysis according to year of publication
(see Additional file 2 for search strategy). Two cases
were presented in detail to illustrate the usefulness of
cumulative subgroup analysis. The first case study used
data from an IPD meta-analysis of beta blockers for
heart failure [16], and the second case study used data
from an IPD meta-analysis that compared treatment
effects for connective tissue disease-associated pulmon-
ary arterial hypertension (PAH) and for idiopathic PAH
[17]. Data from the two case studies were used to
conduct cumulative subgroup analyses. The relevant
subgroup analyses in publications of clinical trials and
aggregate data meta-analyses were also examined, and
compared with the results of the IPD meta-analyses.
Computer simulations
Computer simulations were conducted to assess true
and false positive rates of conventional and cumulative
subgroup analyses in trials using different input parame-
ters in terms of the assumed subgroup effects and
sample size (see Additional file 3 for simulation methods
and input values). A series of sequentially ordered RCTs
were simulated. For each of the simulated trials, the
computer programme randomly generated individual
patients according to distributions of assumed values of
input parameters, and the simulated individual patients
were randomly allocated to a control and a treatment
arm. Simulated patients belong to different subgroups
according to four independent characteristics (X1, X2, X3
and X4) at baseline, and subgroup analyses were con-
ducted in each simulated trial by these baseline charac-
teristics. It is assumed that only X1 is an effect modifier,
and the other three factors (X2, X3, and X4) are not truly
associated with the treatment effect. The treatment
effect for patients with X1 (i.e. X1 = 1) is greater than
patients without X1 (i.e. X1 = 0). The simulated subgroup
effect is measured by ratio of odds ratios (ROR), which
is assumed to be ROR less than 1.0 for patients with X1 =
1 versus X1 = 0, and ROR = 1.0 for the same comparisons
of patients for X2, X3 and X4. For example, if ROR = 0.8
for patients with X1 and OR = 0.7 for patients without X1,
the treatment effect for patients with X1 will be OR =
0.7 × 0.8 = 0.56. We used logistic regression model with an
interaction term to conduct subgroup analyses in the
simulated trials. In the simulation we calculated P values
for subgroup effect each time a new trial was added to the
analysis, and the observation of any statistically significant
subgroup effect was not used to stop the cumulative
subgroup analysis early before all relevant trials were
included. For each scenario, 5000 replications were simu-
lated to estimate the statistical power and the rate of type
I error in subgroup analyses.
Data analyses and computer simulations were
performed using Stata/IC 13 and R language [18]. Statis-
tical significance was defined as two-sided P ≤ 0.05.
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Results
Case study 1: beta blockers for heart failure
Published in 2014, an IPD meta-analysis of 10 RCTs found
that the use of beta blockers reduced all-cause mortality
for patients with heart failure and sinus rhythm, but not
for those with heart failure plus atrial fibrillation at base-
line [16]. The subgroup effect was statistically significant
(P = 0.002 for interaction with baseline rhythm). Using
reported hazard ratios for patients with sinus rhythm and
those with atrial fibrillation, we estimated the ratio of haz-
ard ratios (RHR) between the two subgroups in each of
the 10 RCTs (Fig. 1). There was no statistically significant
heterogeneity in RHRs across RCTs (I2 = 22.7%, P = 0.23),
with a pooled RHR of 0.77 (95% CI, 0.64–0.93; P = 0.007).
Results of cumulative subgroup analysis revealed that the
subgroup effect reached statistical significance by 1999
(pooled RHR = 0.67; 95% CI, 0.46–0.98; P < 0.05), when
five RCTs had been published with a total of 5180
patients. The overall subgroup effect had not been materi-
ally changed since 1999, with five more RCTs and 13,075
more patients (Fig. 1). That is, the significant subgroup
effect could have been detected in cumulative subgroup
analysis 15 years earlier and with 71.6% less patients than
the IPD meta-analysis published in 2014 [16] which first
reported it.
Subgroup analysis stratified by baseline rhythm was not
reported in publications of the main results in the 10
RCTs [19–28]. After the publication of the main results,
subgroup results by cardiac rhythm at baseline were pre-
sented in subsequent reports of the four trials [29–32].
The first was published in 2001 [32], and found statisti-
cally significant interaction between treatment and rhythm
(P < 0.01) using data from the CIBIS-II trial [23]. Although
there were numerous aggregate data meta-analyses on
beta blockers for heart failure, we identified only one
meta-analysis, published in 2013, that performed sub-
group analysis by baseline rhythm [33], and which
included published data from four trials [29–32].
Case study 2: treatment for pulmonary arterial
hypertension
An IPD meta-analysis included 11 placebo-controlled
RCTs that evaluated drugs for pulmonary arterial hyper-
tension (PAH) [17]. For the improvement in 6-minute
walk distance, the IPD meta-analysis found that treatment
for connective tissue disease-associated PAH was less
effective than for idiopathic PAH (Fig. 2). Using data from
this IPD meta-analysis, cumulative subgroup analysis
revealed that the interaction between treatment and diag-
nosis became statistically significant (P < 0.05) by 2008,
when eight RCTs involving a total of 1644 patients had
been published (Fig. 2). The significant subgroup effect
was detectable 6 years earlier, and with 1118 less patients,
than the IPD meta-analysis which first reported it.
Although subgroup analysis by aetiology was
mentioned in most of the included trials, no significant
subgroup effect by diagnosis was reported in original
publications of the included RCTs [34–43]. For example,
data from the ARIES-2 trial showed a statistically signifi-
cant subgroup effect (Fig. 2), which was not reported in
the original publication of the trial [40]. Subgroup
analysis by aetiology was not conducted in any of aggre-
gate data meta-analyses of trials that recruited patients
with both connective tissue disease-associated PAH and
idiopathic PAH [44–47].
Results of computer simulations
Table 1 shows rates of true and false positive subgroup
effects (P ≤ 0.05) observed in simulated trials under vari-
ous scenarios. As expected, the true positive rates
Fig. 1 Beta blockers for heart failure: meta-analysis and cumulative subgroup analysis for differences in treatment effect between patients with
sinus rhythm (SR) and those with atrial fibrillation (AF) at baseline
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(statistical power) are associated with the subgroup ef-
fect (ROR), sample size, event rate in the control arm,
and the proportion of patients in the X1 subgroup. The
false positive rates (type I error) for each of the three
variables (X2, X3 and X4) are about 5%, corresponding to
the definition of statistical significance used (P ≤ 0.05).
However, the false positive rate will be inflated (to about
14.3%) if it is calculated by identifying at least one false
positive subgroup effect among all subgroup analyses by
X2, X3 and X4.
Results of the cumulative subgroup analyses that used
data from simulated trials are shown in Table 2. Given
the assumed subgroup effect and sample size, the true
positive rate was only about 10% with a single trial, 15%
with two trials, and increased to about 80% with 18 trials
(Table 2). For individual variables that are not associated
with the treatment effect, the false positive rates in cu-
mulative subgroup analyses were about 5%, correspond-
ing to the defined statistical significance at P ≤ 0.05
(Table 2).
Discussion
Although subgroup analyses in randomised trials have
well-known limitations, such as inadequate statistical
power and inflated false positive rate, identification of
subgroup effects is important for clinical practice and
further research. The results of the two case studies and
computer simulations presented in this paper indicate
that cumulative subgroup analysis should be used to
overcome limitations of isolated subgroup analyses in
trials, and to encourage appropriate conduct, complete
reporting and timely synthesis of subgroup analyses in
clinical trials.
The detection of differences in effect between sub-
groups usually requires larger sample sizes than the
evaluation of the overall treatment effect, unless the ef-
fects are in opposite directions for different subgroups.
The statistical power to detect meaningful subgroup ef-
fects is unlikely to be sufficient in a single trial, and it is
necessary to shift the focus from subgroup analyses in
separate trials to subgroup analyses involving all related
trials. Although IPD meta-analyses have been increas-
ingly used for this purpose, cumulative subgroup ana-
lysis may detect subgroup effects much earlier than IPD
meta-analyses. The early identification of important
Fig. 2 Meta-analysis and cumulative subgroup analysis of differences in treatment effect between idiopathic (iPAH) and connective tissue disease-
associated pulmonary arterial hypertension (cPAH)
Table 1 True and false positive rates of significant subgroup
effects in simulated trials under different scenarios
Variables Input
values
True
positive
False positive
X1 X2 X3 X4 Any of X2,
X3, X4
Ratio of odds
ratios (ROR)
0.90 6.2% 4.9% 5.0% 5.0% 14.2%
0.80 10.3% 5.0% 5.1% 4.9% 14.2%
0.70 17.9% 4.8% 5.0% 5.0% 14.1%
No. of patients
per arm
200 7.5% 4.9% 4.9% 5.1% 14.1%
400 10.1% 5.0% 5.0% 4.8% 14.2%
600 12.6% 5.1% 5.0% 4.8% 14.2%
Event rate in the
control arm
0.20 8.7% 4.9% 5.1% 5.0% 14.3%
0.30 10.2% 5.2% 5.1% 5.1% 14.6%
0.40 11.3% 5.1% 4.9% 5.1% 14.4%
Proportion of patients
belonging to a subgroup
20% 8.0% 4.6% 5.0% 4.9% 14.2%
30% 9.3% 5.1% 4.9% 4.9% 14.4%
40% 10.0% 5.3% 4.9% 5.1% 14.5%
Except for varying input values shown in the table, the following basic input
parameters were used for other variables: No. of trials = 10; No. of patients per
arm = 400; OR = 0.7; event rate in the control arm = 0.3; heterogeneity
variance = 0.01; ROR = 0.8; proportion of patients with X1 = 0.4. Positive rates
were calculated based on 5000 simulations for each scenario (with a given set
of input parameters)
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subgroup effects may help clinicians in patient care, and
to inform the design and analysis of further research
[48]. After the publication of IPD meta-analysis on beta
blockers for heart failure in 2014 [16], there are still
debates about the use of beta blockers for patients with
heart failure and atrial fibrillation. For example, the re-
sults of the IPD meta-analysis was dismissed as a “retro-
spective subgroup analysis” in the European Society of
Cardiology 2016 Guidelines for the Diagnosis and Treat-
ment of Acute and Chronic Heart Failure [49]. Had the
cumulative subgroup analysis been reported by 1999, the
observed subgroup effect would have been prospectively
investigated in the subsequent large scale trials, and po-
tential mechanisms might have been better investigated.
Inflated false positive rate (type I error) is often used as
a reason to restrict the conduct of multiple subgroup
analyses in clinical trials. However, inflated false positive
findings depend on the following two conditions: selective
reporting of statistically significant results of multiple sub-
group analyses, and a variety of significant subgroup
effects when defined by different patient characteristics.
The first problem, selective reporting, is not unique to
subgroup analysis [50]. It can be addressed by complete
reporting of all subgroup analyses conducted, and by
clearly stating whether the subgroup analyses reported are
pre-specified or post hoc. In addition, the cumulative sub-
group analysis should not be stopped early when a statisti-
cally significant subgroup effect is observed, particularly at
its early stage with only a few included trials. Irrespective
of currently estimated subgroup effects, data from all sub-
sequent trials conducted for various reasons should be
continuously added to the cumulative subgroup analysis.
The second problem may be of limited relevance in prac-
tice because it makes little sense to merge subgroup
effects defined by different patient variables. For example,
purely by chance, the treatment effect may be associated
with age in a trial, and with different baseline variables in
other trials. The results of subgroup effect by age, or by
another variable, should be interpreted separately from
other subgroup effects and based on pooled data from all
related trials. For the same subgroup variable, the rate of
false positive subgroup effect will not be inflated, and will
correspond well with the statistical significance level
adopted in both conventional and cumulative subgroup
analyses (Tables 1 and 2). In addition, the possible harms
due to false positive subgroup effects in individual trials
will be minimal in practice when clinical guidelines are
developed after rigorously assessing the validity of all
available evidence [51].
Subgroup analyses in clinical trials may be used to test
or generate hypotheses on subgroup effects [2, 52]. Given
limited statistical power and lack of clear prior under-
standing of important subgroup variables, subgroup
analyses should be generally considered as hypothesis-
generating when single trials are considered in isolation.
With the concept of cumulative subgroup analysis, a
subgroup analysis in the first trial or a few early trials is
for the purpose of hypothesis generation, but the same
subgroup analysis in subsequent trials may be considered
as hypothesis testing. Because it may be difficult to decide
whether a subgroup analysis is hypothesis-testing or
hypothesis-generating, a Bayesian approach may provide a
more convenient theoretical framework for cumulative
subgroup analysis [53]. Analogous to the Bayesian method
of combining prior and new evidence, a cumulative
subgroup analysis continuously incorporates existing
information with data from a new trial.
Data on patient characteristics at baseline are routinely
collected in randomised controlled trials for multiple
purposes, including a description of study population,
assessment of comparability of trial groups, adjusting for
possible confounding factors, and conduct of subgroup
analyses [54]. During the past several decades, subgroup
analyses in trials have not been encouraged [10]. Conse-
quently, data on baseline characteristics collected in
Table 2 True and false positive rates in cumulative subgroup
analysis using data from simulated trials
No. of trials
sequentially
included
No. of total
patients
involved
True positive False positive
X1 X2 X3 X4
1 800 9.8% 4.8% 5.4% 5.2%
2 1600 14.8% 4.7% 5.3% 4.5%
3 2400 19.7% 5.1% 5.5% 5.0%
4 3200 25.7% 5.1% 5.5% 5.3%
5 4000 30.7% 4.9% 5.4% 4.6%
6 4800 36.4% 5.0% 5.3% 4.9%
7 5600 41.3% 5.4% 5.5% 4.6%
8 6400 46.0% 5.5% 5.2% 4.7%
9 7200 50.7% 5.5% 5.4% 4.5%
10 8000 54.4% 5.2% 5.2% 4.9%
11 8800 58.3% 5.5% 5.3% 4.9%
12 9600 61.6% 5.2% 4.9% 4.5%
13 10,400 65.2% 5.2% 5.3% 4.7%
14 11,200 68.9% 5.5% 5.3% 4.9%
15 12,000 71.9% 5.3% 5.5% 4.9%
16 12,800 74.4% 5.5% 5.4% 4.6%
17 13,600 77.1% 5.7% 5.5% 4.5%
18 14,400 79.6% 5.7% 5.1% 4.8%
19 15,200 82.0% 5.9% 4.7% 4.7%
20 16,000 83.8% 5.7% 4.6% 4.7%
Except for varying input values shown in the table, the following basic input
parameters were used for other variables: No. of patients per arm = 400;
OR = 0.7; event rate in the control arm = 0.3; heterogeneity variance = 0.01;
ROR = 0.8; proportion of patients with X1, X2, X3 and X4 = 0.4. Positive rates
were based on 5000 simulations
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trials have been under-used, or completely wasted, for
the purpose of subgroup analysis. According to the rec-
ommended criteria for credible subgroup analyses [9],
the number of subgroup analyses in a trial should be no
more than five. Another recommended criterion for
credible subgroup analyses is whether subgroup effects
across related studies are consistent [9], which will be
impossible to assess if the same subgroup analysis has
not been conducted and reported in other related stud-
ies. The argument that only a few pre-specified subgroup
analyses should be conducted in a trial conflicts with the
need to compare and combine results of the same sub-
group analysis from all related trials [3]. The current
emphasis on avoiding false positive subgroup effects has
restricted the conduct and reporting of exploratory sub-
group analyses in trials, resulting in a waste of research
data and missing opportunities of detecting subgroup
effects that are meaningful for clinical practice or
additional research [2, 48].
Inaccessibility and lack of full information are avoidable
waste in biomedical research [55]. Subgroup analyses in
meta-analyses using published data are often very limited
or impossible due to inadequate reporting of results of
subgroup analysis in trials [2, 12]. The development of
IPD meta-analyses has facilitated the identification of im-
portant subgroup effects. However, trial data on subgroup
effects have been wasted before the conduct of IPD
meta-analyses, and continue to be wasted where IPD
meta-analyses remain unavailable, although the magnitude
of such waste is currently unclear. Therefore, more IPD
meta-analyses of existing trials should be conducted to
identify meaningful subgroup effects. In future, explora-
tory subgroup analyses using full data on patient
characteristics at baseline should be encouraged.
Subgroup analyses in clinical trials should be con-
ducted using appropriate statistical tests of interactions,
and reporting of subgroup analyses should be complete,
with sufficient information to be included in cumulative
analyses. To conduct cumulative subgroup analysis, the
same or similar definitions of subgroups of interest need
to be adopted in related clinical trials. First, cumulative
subgroup analyses should be taken into account in mak-
ing decisions about data collection at the design stage.
Patient subgroups could be defined according to patient
baseline characteristics using data routinely collected in
clinical trials. Ideally, increased sharing of trial data may
enable prospective IPD meta-analysis with cumulative
subgroup analyses that starts when data from the first
two RCTs are available and is repeated when a new RCT
is completed. Prospective IPD meta-analysis will also
allow the subgroups to be defined in the same way, for
example, using the same cut-points between subgroups.
The usefulness of cumulative subgroup analysis will be
limited when the number of related trials is very small.
Our search of PubMed (see Additional file 2 for search
strategy) identified 60 IPD meta-analyses published in
2014 and only three provided sufficient data for cumula-
tive subgroup analysis. We discussed in detail only two
cases to illustrate the usefulness of cumulative subgroup
analyses for clinical practice and further research. We
believe that our study will inspire others to conduct
more cumulative subgroup analyses using data collected
in existing and future IPD meta-analyses.
Conclusions
Without selective reporting, multiple tests of the same
interaction between a treatment and a subgroup variable
in related trials are not inherently associated with inflated
rate of false subgroup effects. To avoid waste of research
data and facilitate the early detection of important sub-
group effects, subgroup analyses should be more widely
conducted in clinical trials and completely reported. Sub-
group analyses need to be consistently conducted across
related trials using appropriate statistical methods, and
their reporting should be complete, with sufficient data to
be included in cumulative subgroup analysis.
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